Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke
Phase 2
- Conditions
- Health Condition 1: null- Ischemic Stroke
- Registration Number
- CTRI/2012/05/002702
- Lead Sponsor
- Pfizer Limited
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 240
Inclusion Criteria
1.Diagnosis of ischemic stroke with an onset within 72 hours prior to start of study agent administration, male or female.
2.Supratentorial ischemic stroke involving the cortex documented by neurological exam and confirmed by MRI.
3.Stroke involving upper extremity.
4.Subjects who received thrombolytic therapy may be enrolled and the use of antiplatelet is acceptable.
Exclusion Criteria
1.Any other severe acute or chronic medical or psychiatric condition besides the stroke.
2.Women of child bearing potential.
3.Uncontrolled hypertension.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method